Skip to main content
. 2020 Dec 28;22(1):199. doi: 10.3390/ijms22010199

Table 1.

Animal and human studies using antibiotics.

Conditions Treatment Main Results Ref
Animal EtOH-induced liver injury in obese mice Rifaximin (↓): ALT, TG
(↑): Proportion of the Bacteroidales
[59]
Human HE Rifaximin (↓): Recurrent encephalopathy [61]
Cirrhosis developing candidemia Rifaximin (↓): Rate of candidemia [62]
Cirrhotic patients with refractory ascites Rifaximin (↑): Ascites and survival of cirrhotic patients [63]
Cirrhosis Rifaximin-α No effects on macrophage activation and disruption of fibrosis [64]
Cirrhosis Rifaximin (↓): Veillonellaceae, secondary/primary BA ratios [65]
Advanced cirrhosis Norfloxacin (↓): Incidence of Gram-negative bacterial infection
(↑): Survival of patients with low ascites protein concentration
[66]
Cirrhosis Poorly/non-absorbable antibiotics (↓): Hepatic venous pressure gradient [70]
HE (review) Antibiotics
Rifaximin
Improve cognition, inflammation, quality -of-life and driving simulator performance [60]

↑ indicates an increase in condition, ↓ indicates a decrease in condition, ALT, alanine aminotransferase; BA, bile acids; HE, hepatic encephalopathy; TG, triglycerides